Mavacamten and Aficamten Show Promise in Phase 3 Trials for HCM

The results from pivotal Phase 3 trials for cardiac myosin inhibitors, specifically mavacamten and aficamten, have demonstrated significant clinical benefits for patients with hypertrophic cardiomyopathy (HCM). Dr. Masri presented these findings, highlighting critical data from the EXPLORER-HCM trial, a randomized, placebo-controlled study that showcased substantial improvements in peak oxygen consumption and New York Heart Association (NYHA) functional class among symptomatic obstructive HCM patients. The results indicated notable reductions in left ventricular outflow tract (LVOT) gradients, alongside favorable changes in biomarkers related to myocardial stress and injury.

The subsequent VALOR-HCM trial focused on patients already considered for septal reduction therapy. It revealed that mavacamten could effectively defer or prevent the need for invasive interventions in a significant number of participants by lowering gradients and alleviating symptoms. Dr. Maron summarized the outcomes of the Phase 3 experience with aficamten, particularly the findings from the SEQUOIA-HCM trial. This study similarly demonstrated a marked reduction in gradients, consistent symptom relief, and improvements in health status metrics, including NYHA class and scores from the Kansas City Cardiomyopathy Questionnaire.

Across these studies, both physicians emphasized that a high percentage of treated patients achieved LVOT gradients below 30 mm Hg. This correlation between hemodynamic improvements and functional gains positions cardiac myosin inhibitors as high-benefit therapies, potentially restoring a good or excellent quality of life for many patients.

Focus on Safety and Monitoring Requirements

The discussion also addressed safety concerns, particularly regarding treatment-emergent systolic dysfunction. Dr. Maron noted that both mavacamten and aficamten could reduce left ventricular ejection fraction (LVEF) below the recommended range in a minority of patients. In response, the U.S. Food and Drug Administration (FDA) has mandated Risk Evaluation and Mitigation Strategy (REMS) programs for both drugs. These programs focus on serial echocardiographic monitoring and algorithmic dose adjustments to mitigate risks.

Dr. Masri highlighted that aficamten was developed using echocardiographic guidance alone, without requiring drug-level monitoring. The trial showed a lower incidence of systolic dysfunction and was not associated with clinical heart failure events in the SEQUOIA-HCM trial. These attributes, along with fewer drug–drug interactions and a more flexible titration process, contribute to a streamlined and clinician-friendly REMS structure for aficamten.

The promising data from these trials underscore the potential of cardiac myosin inhibitors in advancing treatment options for patients with HCM, offering hope for improved health outcomes and quality of life.